Portillo et al. engineered expanded NK cells containing a normal complement of inhibitory and activating receptors derived from healthy donors and breast cancer patients with a HER2-targeting CAR (HER2 CAR-NK) and evaluated its cytotoxicity against malignant and non-malignant cells. Compared to non-transduced and HER2 CAR T cells, HER2 CAR NK cells demonstrated enhanced cytotoxicity against HER2-expressing breast and ovarian cancer cells in vitro and were less reactive against HER2-expressing healthy human lung epithelial cells. TGFβ and PGE2 suppressed the cytotoxicity of expanded NK cells, but not of CAR-NK cells.
Contributed by Shishir Pant
ABSTRACT: Despite the remarkable success of chimeric antigen receptor (CAR)-T cells against hematologic malignancies, severe off-tumor effects have constrained their use against solid tumors. Recently, CAR-engineered natural killer (NK) cells have emerged as an effective and safe alternative. Here, we demonstrate that HER2 CAR-expression in NK cells from healthy donors and patients with breast cancer potently enhances their anti-tumor functions against various HER2-expressing cancer cells, regardless of MHC class I expression. Moreover, HER2 CAR-NK cells exert higher cytotoxicity than donor-matched HER2 CAR-T cells against tumor targets. Importantly, unlike CAR-T cells, HER2 CAR-NK cells do not elicit enhanced cytotoxicity or inflammatory cytokine production against non-malignant human lung epithelial cells with basal HER2 expression. Further, HER2 CAR-NK cells maintain high cytotoxic function in the presence of immunosuppressive factors enriched in solid tumors. These results show that CAR-NK cells may be a highly potent and safe source of immunotherapy in the context of solid tumors.